Immediate Impact

2 from Science/Nature 83 standout
Sub-graph 1 of 23

Citing Papers

Lorlatinib Versus Crizotinib in Patients With Advanced ALK -Positive Non–Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study
2024 Standout
Targeting KRAS in cancer
2024 Standout
1 intermediate paper

Works of D. Kim being referenced

P52.03 Efficacy of Sotorasib in KRAS p.G12C-Mutated NSCLC with Stable Brain Metastases: A Post-Hoc Analysis of CodeBreaK 100
2021
MA11.08 Patient-Reported Outcomes from the Randomized Phase 3 CROWN Study of First-Line Lorlatinib versus Crizotinib in ALK+ NSCLC
2021

Author Peers

Author Last Decade Papers Cites
D. Kim 316 269 122 16 339
J.C.-H. Yang 277 260 91 12 345
Minal Mehta 298 277 90 19 367
M.R. García Campelo 293 276 114 34 373
Mauricio Cuello 245 184 97 17 321
You Lu 292 239 57 22 321
Janice J.N. Li 211 171 109 16 317
Michela Lia 239 142 109 15 314
Masayuki Yasugi 236 233 131 22 348
Laura Schubert 276 194 195 13 386
Graham Cohen 154 199 101 18 303

All Works

Loading papers...

Rankless by CCL
2026